Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.
作者信息
Eadie Laura N, Lagonik Elias, Page Elyse C, Schutz Caitlin E, Heatley Susan L, McClure Barbara J, Forgione Michelle O, Yeung David T, Hughes Timothy P, White Deborah L
机构信息
Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.
出版信息
Blood. 2024 Aug 29;144(9):1022-1026. doi: 10.1182/blood.2024024776.
PMID:38848536
Abstract
摘要
Zotero 插件